CLINUVEL PHARMACEUTICALS LIMITED (CUV)
Share Price Analysis and Chart

Enter the company code or Name for stock analysis:

CUV - CLINUVEL PHARMACEUTICALS LIMITED

FNArena Sector : Pharmaceuticals & Biotech/Lifesciences
Year End: June
GICS Industry Group : Pharmaceuticals, Biotechnology & Life Sciences
Debt/EBITDA: 0.02
Index: ASX300 | ALL-ORDS

Clinuvel is a biopharmaceutical company that develops and commercialises treatments for patients with genetic, metabolic and life threatening disorders. The company was founded and listed in 2001.

LAST PRICE CHANGE +/- CHANGE % VOLUME

$14.98

25 Jul
2024

-0.120

OPEN

$15.02

-0.79%

HIGH

$15.13

24,323

LOW

$14.85

TARGET
$18.75 25.2% upside
Franking for last dividend paid out: 100%
OTHER COMPANIES IN THE SAME SECTOR
1AD . ACR . ACW . ADO . AFP . AGH . AGN . ARX . AVH . BIO . BOT . CSL . DXB . EOF . GSS . HXL . IDT . IMM . IMU . IVX . LGP . MAP . MDC . MSB . MVP . MYX . NEU . NXS . OCC . OPT . OSL . PAR . PER . PNV . PYC . RAC . RCE . SPL . TLX . TRP . VIT . ZNO .
FNARENA'S MARKET CONSENSUS FORECASTS
CUV: 1
Title FY22
Actual		 FY23
Actual		 FY24
Forecast		 FY25
Forecast
EPS (cps) xxx 61.9 68.9 xxx
DPS (cps) xxx 5.0 6.3 xxx
EPS Growth xxx 46.6% 11.2% xxx
DPS Growth xxx 25.0% 26.7% xxx
PE Ratio xxx N/A 21.7 xxx
Dividend Yield xxx N/A 0.4% xxx
Div Pay Ratio(%) xxx 8.1% 9.2% xxx

Dividend yield today if purchased 3 years ago: 0.17%

DIVIDEND YIELD CALCULATOR

Dividend Yield Today On Last Actual Payout :

 0.33

Estimated Dividend Growth
(Average Of Past Three Years)

  %

Amount Invested

 $ 

Tell Me The Dividend After This Many Years
Past performance is no guarantee for the future. Investors should take into account that heavy swings in share price or exceptional circumstances (a la 2009) can have a significant impact on short term calculations and averages

Last ex-div: 06/09 - ex-div 4c (franking 100%)

HISTORICAL DATA ARE ALL IN AUD
Copyright © 2024 FactSet UK Limited. All rights reserved
Title 201820192020202120222023
EPS Basic xxxxxxxxxxxxxxx61.9
DPS All xxxxxxxxxxxxxxx5.0
Sales/Revenue xxxxxxxxxxxxxxx78.3 M
Book Value Per Share xxxxxxxxxxxxxxx333.2
Net Operating Cash Flow xxxxxxxxxxxxxxx36.9 M
Net Profit Margin xxxxxxxxxxxxxxx39.08 %

EPS Basic

DPS All

Sales/Revenue

Book Value Per Share

Net Operating Cash Flow

Net Profit Margin

Title 201820192020202120222023
Return on Capital Employed xxxxxxxxxxxxxxx21.09 %
Return on Invested Capital xxxxxxxxxxxxxxx20.97 %
Return on Assets xxxxxxxxxxxxxxx18.04 %
Return on Equity xxxxxxxxxxxxxxx21.09 %
Return on Total Capital xxxxxxxxxxxxxxx27.98 %
Free Cash Flow ex dividends xxxxxxxxxxxxxxx33.9 M

Return on Capital Employed

Return on Invested Capital

Return on Assets

Return on Equity

Return on Total Capital

Free Cash Flow ex dividends

Title 201820192020202120222023
Short-Term Debt xxxxxxxxxxxxxxx0 M
Long Term Debt xxxxxxxxxxxxxxx1 M
Total Debt xxxxxxxxxxxxxxx1 M
Goodwill - Gross xxxxxxxxxxxxxxx0 M
Cash & Equivalents - Generic xxxxxxxxxxxxxxx157 M
Price To Book Value xxxxxxxxxxxxxxx5.37

Short-Term Debt

Long Term Debt

Total Debt

Goodwill - Gross

Cash & Equivalents - Generic

Price To Book Value

Title 201820192020202120222023
Capex xxxxxxxxxxxxxxx1.0 M
Capex % of Sales xxxxxxxxxxxxxxx1.31 %
Cost of Goods Sold xxxxxxxxxxxxxxx28 M
Selling, General & Admin. Exp & Other xxxxxxxxxxxxxxx10 M
Research & Development xxxxxxxxxxxxxxx1 M
Investments - Total xxxxxxxxxxxxxxx0 M

Capex

Capex % of Sales

Cost of Goods Sold

Selling, General & Admin. Exp & Other

Research & Development

Investments - Total

EXPERT VIEWS
Display All Commentary

Sentiment Indicator

0.5

No. Of Recommendations

3
BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Morgans

xx/xx/xxxx

3

xxxxxxxxx xx xxxx xxxx xxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Ord Minnett

19/06/2024

2

Accumulate

$18.00

20.16%

The approval of a Phase 2a clinical trial to evaluate afamelanotide as a treatment for early-stage Parkinson has not triggered any adjustments to Ord Minnett's $18 fair value estimate or its Accumulate rating.

It's too early to start drawing conclusions, today's report states.

The broker highlights Clinuvel Pharmaceuticals is exploring additional indications for its current prime product, Scenesse, including vitiligo.

Ord Minnett sees the stock as undervalued, seeing the market as being too cautious on the speed and extent of the commercial rollout of Scenesse.

FORECAST
Ord Minnett forecasts a full year FY24 dividend of 7.00 cents and EPS of 71.20 cents.
Ord Minnett forecasts a full year FY25 dividend of 8.00 cents and EPS of 82.40 cents.

Bell Potter

xx/xx/xxxx

1

xxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial
EXTRA COVERAGE
Display All Commentary

No. Of Recommendations

1

Please note: unlike Broker Call Report, BC Extra is not updated daily. The info you see might not be the latest. FNArena does its best to update ASAP.

BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Wilsons

27/06/2024

1

Overweight

$31.38

109.48%

Wilsons highlights the lucrative leverage opportunities provided by the Scenesse label expansion into vitiligo, and the launch
into the Adrenocorticotropic Hormone (ACTH) market in the US.

As management at Clinuvel Pharmaceuticals keeps providing more information around expectations and preparation work, the broker suggest the opportunity is being materially undervalued by the wider market.

The company is aiming to leverage Scenesse into more indications (vitiligo, XP), and add new pharmaceutical product lines (Neuracthel), as well as diversify into photocosmetics (with a broader consumer audience), explains the broker.

The Overweight rating is retained and the target rises to $31.38 from $25.46.

FORECAST
Wilsons forecasts a full year FY24 dividend of 7.40 cents and EPS of 61.60 cents.
Wilsons forecasts a full year FY25 dividend of 8.90 cents and EPS of 59.20 cents.
Access Stockbroker Research History >

CUV STOCK CHART

FNArena News on CUV

1
Rudi’s View: Rate Cuts, Growth & Small Caps

Jul 18 2024 - Rudi's View
2
Weekly Ratings, Targets, Forecast Changes – 12-07-24

Jul 15 2024 - Weekly Reports
3
Rudi’s View: Gold, Healthcare, Staples & Copper

Jul 11 2024 - Rudi's View
4
Rudi’s View: Met Coal, Banks, GenAi & Buying-The-Dip

Jul 04 2024 - Rudi's View
5
Australian Broker Call *Extra* Edition – Jun 27, 2024

Jun 27 2024 - Daily Market Reports

Latest Pharmaceuticals & Biotech/Lifesciences News

1
CSL Shares Breaking Free

Jul 23 2024 - Technicals
2
Dr Boreham’s Crucible: SDI

Jul 19 2024 - Small Caps
3
‘Defensive’ Pharmaceutical Wholesalers In Focus

Jul 18 2024 - Australia
4
Twists And Turns Of Telix And Australian Biotech

Jul 10 2024 - Small Caps
5
Dr Boreham’s Crucible: Radiopharm Theranostics

Jul 03 2024 - Small Caps
6
Dr Boreham’s Crucible: Island Therapeutics

Jun 17 2024 - Small Caps
7
Dr Boreham’s Crucible: Amplia Therapeutics

Jun 05 2024 - Small Caps
8
Is The Long Wait For CSL About To End?

May 30 2024 - Technicals
9
Dr Boreham’s Crucible: Invion

May 13 2024 - Small Caps
10
Dr Boreham’s Crucible: Race Oncology

Apr 09 2024 - Small Caps